The SARS-CoV-2 virus responsible for the COVID-19 pandemic severely affected the respiratory system and had a significant impact on people with respiratory illnesses such as asthma or COPD in Canada; hence, the demand for both respiratory diagnostics and therapeutic devices increased significantly during the peak of the COVID-19 pandemic in Canada. For instance, an article published by the journal Physics of Fluids in January 2021 reported a surge in demand for oxygen concentrators and ventilators in hospitals across Canada. Thus, COVID-19 increased the demand for respiratory devices during the pandemic. However, in the current scenario, with the decrease in COVID-19 cases, the demand for respiratory devices in the country may get reduced compared to the beginning of the pandemic, but with the emergence of new SARS-CoV-2 strains and other respiratory disorders, the market is expected to witness significant growth over the forecast period.
The factors that are driving the studied market in the country are the increasing prevalence of respiratory disorders, such as COPD, TB, asthma, and sleep apnea, and technological advancements and their increasing applications in the homecare setting. For instance, in March 2022, the Government of Canada reported that in 2020, 4.7 active TB cases were reported per 100,000 people. The corresponding rate for females was 4.2 cases per 100,000 population, compared to 5.1 cases per 100,000 population for men. Similarly, an article published by Scientific Reports in August 2022 reported that in Canada, 3.8 million people lived with asthma in the year 2021. Thus, high cases of respiratory disorders are increasing the demand for respiratory devices, thereby driving the market.
Technological advancements and new product launches are also driving the market in the country. For instance, in November 2021, Ezzy Group Inc., Toronto, reported the successful development of the company's first-ever compostable surgical-grade face mask manufactured in Canada. These compostable masks are ASTM F-2100 certified and Health Canada approved. Similarly, in February 2022, Aptar Pharma launched HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device in North America. Thus, such product launches are providing better respiratory services to the people in the country, thereby driving the market.
Thus, due to the increasing prevalence of respiratory disorders, such as COPD, TB, asthma, and sleep apnea, and technological advancements and increasing applications in the homecare setting, the market is expected to witness significant growth over the forecast period. However, the high cost of respiratory devices may slow down the growth of the studied market.
Canada Respiratory Devices Market Trends
Sleep Test Devices Segment is Expected to Witness a Significant Growth Over the Forecast Period.Sleep apnea is a potentially serious sleep disorder in which breathing repeatedly stops and starts. Sleep apnea has a very high prevalence in Canada; however, a major portion of the patients are undiagnosed, which creates a huge economic burden in terms of workplace and road accidents, lost productivity, and comorbid diseases.
The increasing incidence of sleep apnea among Canada's children is also driving the growth of the studied market. For instance, an article published by the Journal of Otolaryngology in August 2021 reported that obstructive sleep apnea (OSA) is common in the pediatric population, with a prevalence of 1%-6% in Canada. Thus, the presence of a high prevalence of sleep apnea is driving the growth of the studied market.
Further, product launches and mergers, acquisitions, and partnerships among key market players in Canada are driving the growth of this segment. For instance, in October 2022, Frequency Exchange Corp., a Canadian wellness company, launched the Frequency Deliver System, which supports recovery from wellness and performance issues while sleeping. Bioenergetics-based Nikki emits frequencies that help restore cellular function within the body's network of 37 trillion cells. Nikki works at night to overcome the physical and emotional trauma she experiences during the day. Thus, such devices are driving the growth of the segment.
So, the growth of this segment over the next few years will be driven by how common sleep apnea is and how technology is changing.
Inhalers Segment is Expected to Witness a Significant Growth Over the Forecast Period.Respiratory inhalers are used to inhale medicines that are an essential part of the treatment for chronic lung diseases. The rapidly increasing prevalence of respiratory disorders across the country is among the significant factors fueling the growth and demand of the respiratory inhaler market. In addition, the increasing demand for treatment options for respiratory disorders and the accessibility of well-developed technologies are also contributing to the growth of this segment. Also, more pollution in the air has made more people need inhalers, which is expected to drive the growth of this segment.
The increasing number of respiratory disorders in the country is driving the demand for this segment. For instance, in November 2022, the Breathe Lung Association reported that one in five Canadians has a serious respiratory disease, such as asthma, COPD, lung cancer, tuberculosis, cystic fibrosis, and respiratory distress syndrome. The source also reported that Canada has one of the highest asthma rates in the world. About 2.7 million Canadians live with asthma. Asthma is the most common work-related lung disease, the third-leading cause of lost work time, and the leading cause of school absenteeism and hospitalization for children. Thus, the increase in asthma and COPD cases is driving the demand for inhalers, thereby driving the growth of this segment.
Also, the geriatric population is more sensitive to respiratory disorders, and the increasing geriatric population in the country is also contributing to the growth of this segment. For instance, in July 2022, the United Nations report stated that there were 7.3 million people in Canada aged 65 and older, and this number is expected to increase to 10.2 million by 2040. Thus, the increasing geriatric population may lead to an increase in respiratory disorders, which may increase the demand for inhalers, thereby driving the growth of this segment.
Furthermore, new product launches and technological developments are fueling the growth of this segment. For instance, in October 2022, AstraZeneca launched the inhaler Breztri Aerosphere, which is now available in Canada after Health Canada's approval. Breztri (budesonide, glycopyrronium, and formoterol fumarate dihydrate) is indicated as a long-term maintenance therapy to reduce exacerbations of chronic obstructive pulmonary disease (COPD) and treat airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema. Thus, such new product launches are driving the growth of the studied market in the country.
Thus, due to the increasing respiratory disorders, increasing geriatric population, increasing air pollutants, and new product launches, these factors are driving the growth of this segment over the forecast period.
Canada Respiratory Devices Market Competitor AnalysisCanada's respiratory devices market is competitive and consists of several players. Some of the companies that are currently dominating the market are Koninklijke Philips N.V., Nihon Kohden Corporation, Medtronic PLC, Gentige AB, General Electronic Company (GE Healthcare), Fisher & Paykel Healthcare Limited, Dragerwerk AG & Co. KGaA, Hamilton Medical AG, Invacare Corporation, and Becton, Dickinson and Company.
Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1.2 Scope of the Study
4.2 Market Drivers
4.2.1 Increasing Prevalence of Respiratory Disorders, such as COPD, TB, Asthma, and Sleep Apnea
4.2.2 Technological Advancements and Increasing Applications in the Homecare Setting
4.3 Market Restraints
4.3.1 High Cost of Devices
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1.2 Sleep Test Devices
5.1.3 Peak Flow Meters
5.1.4 Pulse Oximeters
5.1.6 Other Diagnostic and Monitoring Devices
5.2 By Therapeutic Device
5.2.1 CPAP Devices
5.2.2 BiPAP Devices
5.2.5 Oxygen Concentrators
5.2.8 Other Therapeutic Devices
5.3 By Disposables
5.3.2 Breathing Circuit
5.3.3 Other Disposables
6.1.1 Koninklijke Philips N.V.
6.1.2 Nihon Kohden Corporation
6.1.3 Medtronic PLC
6.1.4 Gentige AB
6.1.5 General Electronic Company (GE Healthcare)
6.1.6 Fisher & Paykel Healthcare Limited
6.1.7 Dragerwerk AG & Co. KGaA
6.1.8 Hamilton Medical AG
6.1.9 Invacare Corporation
6.1.10 Becton, Dickinson and Company
A selection of companies mentioned in this report includes:
- Koninklijke Philips N.V.
- Nihon Kohden Corporation
- Medtronic PLC
- Gentige AB
- General Electronic Company (GE Healthcare)
- Fisher & Paykel Healthcare Limited
- Dragerwerk AG & Co. KGaA
- Hamilton Medical AG
- Invacare Corporation
- Becton, Dickinson and Company